Legend Biotech Corp (NASDAQ:LEGN) reported a 135% year-over-year increase in net trade sales for CARVYKTI, reaching approximately $369 million. The company has treated over 6,000 patients with ...

Under the agreement, GSK will pay up to $2 billion in total cash consideration ... Mitigate Potential Tariffs After Q1 Drug Sales Efimosfermin is a phase 3-ready, investigational specialty ...

First of five Phase 2 trials for AL001 begins in healthy subjects with topline data expected by end of 2025. Preclinical data showed AL001 improved brain absorption with lower blood lithium levels ...

The Colorado-based biotech is currently evaluating ELVN-002, which is designed to inhibit the HER2 pathway in solid tumors, in a pair of phase 1 trials. One of these studies is looking at ELVN-002 ...

The Swift's sales surged 2.5 times due to its new design, highlighting the need for model refreshes. In contrast, the Brezza saw a marginal decline, underscoring the importance of ongoing ...

Chandigarh: The municipal corporation on Wednesday organised a blood donation camp at six different locations in the city. The authority collected a total of 530 units of blood.The mega camp was ...

Legend Biotech Corp (LEGN) reported robust financial results for Q1 2025, driven by significant sales growth of its flagship product, CARVICTI. The company posted total revenues of $195 million ...

Legend Biotech Corporation ... a substantial rise from $24.2 million in Q1 2024, suggesting increased costs associated with the expansion of their sales force. CARVYKTI® received positive CHMP ...

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq ... activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients.

Novo Nordisk (NVO) announced a new $2.2 billion deal with ... The deal with Septerna puts the biotech in charge through the early discovery and dosing phase, and once a lead option is chosen ...

Edesa Biotech, Inc. has announced its financial ... The company is preparing for a Phase 2 study in the U.S. for moderate-to-severe nonsegmental vitiligo, with manufacturing and regulatory ...

EXCLUSIVE: Maya Hawke is set to play Lucia Joyce opposite ... The Veterans have boarded sales on the feature for a Cannes market launch. The biopic is based on the life of Lucia Joyce, the ...